Skip to content
All Podcasts – Lifestyle
Author:
NIELSEN / PRODUCT
CTV’s Data Gap Holding Back Bigger Ad Budgets, New Gracenote Research Finds
May 14, 2026
Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
May 13, 2026
Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
May 5, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
April 17, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.
April 9, 2026
Gen Alpha Leads Shift to AI-Powered Entertainment Search, Discovery and Recommendations
April 8, 2026
FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
April 1, 2026
Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
March 30, 2026
Samsung taps Gracenote to supercharge range of AI initiatives
March 4, 2026
←
Previous Page
1
2